Educational guide
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market - Polypeptide
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”),
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Lifecore and PolyPeptide Announce Collaboration Intended to Offer End-to-End Peptide Manufacturing Solution for U.S. Market
Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and PolyPeptide Laboratories, Inc. (“PolyPeptide”), a global leader in peptide contract development and manufacturing, today announced the signing of a collaboration agreement aimed at providing an integrated, end-to-end solution for peptide-based pharmaceutical customers in the U.S.
The collaboration will leverage PolyPeptide’s strong capabilities in peptide manufacturing and development in combination with Lifecore’s expertise in formulation, fill/finish, and packaging. The companies intend to work together to offer a seamless transition between drug substance (DS) and drug product (DP), which is designed to enable customers to accelerate development timelines, reduce development costs and risks, and enjoy the reliability and regulatory alignment that comes with a fully U.S.-based supply chain.
“This collaboration brings together two leading organizations, each an expert in its field, to deliver value to peptide-based pharmaceutical developers. Together, we expect to optimize product development activities through a range of collaborative studies and assessments, and by streamlining the supply chain, aim to help customers meet their development milestones,” said Mark DaFonseca, chief commercial officer, Lifecore Biomedical.
“By aligning our technical and commercial strengths, we believe we are uniquely positioned to help customers navigate complex development challenges and bring innovative therapies to market faster. Together, the companies anticipate jointly supporting laboratory transfers, equipment comparability, method transfer and release testing, thus ensuring robust technical oversight and quality through the entire process,” added Trishul Shah, global director of business development and head of sales, PolyPeptide.
Download PDF